STOCK MARKET BSE NSE

Apollo Hospitals Bhubaneswar starts antibody cocktail therapy

The decision to administer the antibody cocktail was taken by a board of doctors led by Director (Medical Services) of Apollo Hospitals Dr Ashish Chandra.

Published: 01st June 2021 03:05 PM  |   Last Updated: 01st June 2021 03:10 PM   |  A+A-

The Central Drugs Standards Control Organization has approved the emergency use of monoclonal antibody cocktail. (Photo | Special arrangement)

Express News Service

BHUBANESWAR: Apollo Hospitals in Bhubaneswar began the monoclonal antibody cocktail therapy on a Covid patient on Monday.

The Central Drugs Standards Control Organization (CDSCO) has approved the emergency use of the Covid monoclonal antibody cocktail.

Sources said the 82-year-old man from Bhubaneswar with comorbidities was administered the antibody cocktail (Casirivimab and Imdevimab) on Monday. The patient was admitted to the hospital on May 29 three days after he tested positive for the virus.

The decision to administer the antibody cocktail was taken by a board of doctors led by Director (Medical Services) of Apollo Hospitals Dr Ashish Chandra.

Consultant physician Dr Paresh Jena said the patient tolerated the medication and his condition is improving. “The patient with comorbidities, including heart disease and old brain stroke, was admitted on day 5 of the Covid symptoms. The Covid monoclonal antibodies were given on day 6. We are the first hospital in the State to begin the combination medication,” he said.

ALSO READ | Test positivity rate declines but high share of RATs big concern in Odisha

The antibody cocktail has been recommended for the treatment of mild to moderate Covid-19 in adults and paediatric patients of 12 years or older, weighing at least 40 kg and who are at high risk of developing severe disease and do not require oxygen.

The advantage of the cocktail to be administered once, Dr Jena said, is that it can be used on comorbid patients with heart and renal diseases, cancer and other such illnesses.

“It will prevent the condition of the high-risk patients from worsening further by reducing the risk of progressing to severe disease and fatality by 70 per cent besides shortening the duration of symptoms by four days,” he said.

With health experts advocating for rational use of the Covid-19 monoclonal antibody cocktail, the doctors at the hospital are optimistic that the availability of antibody cocktail can help in minimising disease severity, and play a key role in treatment of high risk patients before their condition worsens. It is, however, not recommended for patients who have moderate or severe disease with hypoxia.

“We hope the cocktail antibody will benefit more comorbid patients with mild symptoms on whom Covid treatment gets delayed due to their other serious comorbid conditions. We are looking forward to patients taking advantage of the treatment,” said senior public relations officer Rakesh Ray.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp